Insmed, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $223.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ritu Baral’s rating is based on several positive developments for Insmed. The company’s recent financial performance has been strong, with Brinsupri’s third-quarter revenue significantly surpassing expectations. This success is attributed to a robust early launch in the non-cystic fibrosis bronchiectasis market, with a notable number of patients and prescribers engaged by the end of September.
Additionally, Insmed’s pipeline shows promise with upcoming trial data and new trials set to begin in the near future. The increase in the price target reflects the enhanced value from Brensocatib in chronic rhinosinusitis without nasal polyps. Furthermore, the company’s global revenue guidance for Arikayce has been raised, indicating continued growth and potential for further success. These factors collectively support the Buy rating given by Ritu Baral.